Discover how the HeadSMART II study is combining blood biomarkers, digital neurocognitive testing and AI to identify patients at risk of persistent TBI symptoms
Guest editorial by Russ Lebovitz, MD, PhD, is CEO and Co-Founder of Amprion
Hear how the Program of Glyco-Immunology and Oncology (PGIO) is deciphering cancer’s ‘glyco code’ to pave the way for more precise diagnostics and next generation immunotherapies
See why accessible, pathology-informed testing is becoming increasingly important for earlier diagnosis, patient stratification, and more efficient neurological care
Kits help reduce complexity while improving consistency and turnaround time
NanoSomiX and Beckman Coulter Diagnostics collaborate to advance EV-based blood tests for neurodegenerative diseases
FDA registration represents an important milestone in expanding access to the technology for healthcare professionals in the United States
ADLM 2026 to explore diabetes milestones, space diagnostics, Alzheimer’s and Down syndrome linkages, and advances in cancer screening and biomarkers
SelectScience interviews leading experts at pivotal conference in London, UK
Targeted proteomics platform company secures $7.5 million to scale commercialization and strategic partnerships
Assay enables laboratories across Europe and other CE-recognizing markets to scale blood-based Alzheimer’s disease testing and advance research into amyloid and tau pathology
The test is being developed for use on Abbott’s Alinity ci-series systems to help enable earlier and more accessible Alzheimer’s diagnosis on a global scale
First-of-its-kind assay by Vector Laboratories and Spatomics enables simultaneous mapping of proteins and glycans on a single slide
New thinking around Bayes’ theorem, sepsis biomarkers, and additive diagnostic value could help unlock tests that improve patient care, even when they fall short of perfection
Expanded partnership with AstraZeneca and Daiichi Sankyo focuses on developing AI-assisted IHC assays for lung cancer biomarker analysis
Quanterix is bridging spatial biology and ultra-sensitive detection to transform cancer research and diagnostics
Collaboration focuses on education, early testing, and improved access to care for patients at risk of HDFN
Despite advances in biomarker testing, real-world data shows progress is not translating into treatment decisions, with the largest patient loss now occurring at the point of treatment decision
Acquisition strengthens Roche’s digital pathology and companion diagnostic portfolio to advance precision medicine
SPEAR overcomes immunoassay complexity and sensitivity limitations in Alzheimer’s and neurodegenerative biomarker research with a homogeneous, wash-free format
Michael Richardson explains how Inotiv is unlocking new insights into disease mechanisms and therapeutic effectiveness using spatial transcriptomics, proteomics, and AI-powered image analytics.
New research and clinical evidence are redefining how clinicians detect and manage preeclampsia, with angiogenic biomarker testing offering earlier, clearer insight into maternal risk
Every biomarker in Aliri’s study-ready panels is carefully selected and rigorously verified for its intended biological context
Yao Chen of Sanofi shares how her team achieves sensitivity, specificity, precision, and robustness in protein biomarker detection
